Cernilton^® (Tablets) Instructions for Use

ATC Code

G04CX (Other preparations for the treatment of benign prostatic hyperplasia)

Clinical-Pharmacological Group

Herbal preparation, used for prostate gland diseases

Pharmacotherapeutic Group

Herbal remedy for the treatment of prostate adenoma

Pharmacological Action

Cernilton^® is a microbiologically fermented extract of pollen from plants of the Gramineae family.

Cernilton^® has anti-inflammatory and anti-edema effects and helps to regulate metabolic processes.

One of the pharmacological properties of the drug is the dose-dependent inhibition of cyclooxygenase and 5-lipoxygenase, which leads to the suppression of the synthesis of inflammatory mediators of the arachidonic acid cascade: prostaglandins and leukotrienes and, as a result, to a reduction in inflammation and edema of the prostate tissue. The drug helps to eliminate the pain syndrome. Cernilton^® has a myorelaxant effect, which leads to relaxation of the smooth muscle cells of the posterior wall of the urethra and improvement of urination.

The drug reduces the volume of the prostate gland by inhibiting 5-alpha-reductase, selectively blocks alpha1-adrenergic receptors of the smooth muscle cells of the urethra, and has an antiandrogenic effect. It helps to improve erectile function.

Pharmacokinetics

No data available.

Indications

As part of complex therapy

• Acute and chronic prostatitis;
• Benign prostatic hyperplasia;
• Benign prostatic hyperplasia in combination with prostatitis.

ICD codes

Dosage Regimen

Tablets

The drug is taken orally 30 min before meals with a small amount of water.

For acute prostatitis, 4 tablets are prescribed 3 times/day. The duration of the treatment course is determined by the attending physician and is usually 3 months.

For chronic prostatitis, 1 tablet is prescribed 3-4 times/day. The duration of the treatment course is determined individually by the attending physician and is usually from 3 to 6 months.

For benign prostatic hyperplasia, 2 tablets are prescribed 3 times/day. The duration of the treatment course is determined individually by the attending physician and is usually from 6 to 12 weeks, but can be increased to 6 months.

Adverse Reactions

Allergic reactions are possible; in rare cases, nausea may occur.

Contraindications

• Hypersensitivity to the components of the drug.

Special Precautions

The use of the drug for chronic bacterial prostatitis is possible only in combination with antibacterial agents, as prescribed and under the supervision of a physician.

Effect on the ability to drive vehicles and mechanisms

Cernilton^® does not affect the ability to engage in potentially hazardous activities requiring increased concentration and speed of psychomotor reactions, including driving vehicles, working with moving mechanisms, work of a dispatcher and operator.

Overdose

To date, no cases of overdose have been observed.

Drug Interactions

There is no information on the interaction of Cernilton^® with other medicinal products.

Storage Conditions

In a dry, light-protected place, at a temperature not exceeding 25°C (77°F). Keep out of reach of children.

Shelf Life

Shelf life – 5 years.

Dispensing Status

Over-the-counter.

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.